A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133
Miles A. Keats(National Institutes of Health), Ji Luo(Center for Cancer Research)
Cited by 19
Related Papers
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
|Proceedings of the National Academy of Sciences|2015|75
One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation
|Cell & Bioscience|2016|13
A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133
|bioRxiv (Cold Spring Harbor Laboratory)|2022|1